Overview

Roll Over Study to Provide Idelalisib to Participants Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820

Status:
Terminated

Trial end date:
2017-12-28

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to provide idelalisib to participants receiving GS-9820 in Gilead-sponsored Study GS-US-315-0102 at the time of study closure.

Phase:

Phase 4

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Idelalisib